Survival results of a randomized, phase III trial of nab-paclitaxel and carboplatin compared with cremophor-based paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung ...
Longitudinal plasma proteomic analysis: A monitoring strategy for NSCLC patients treated with immunotherapy. Radiomic phenotypes of tumor angiogenesis compared with PD-L1 in pre-treatment prediction ...
1don MSN
Carboplatin with chemotherapy increases survival in triple-negative breast cancer: TMC study
Results showed a 77% survival rate in patients below 50 years who used carboplatin, an increase from the 66% without it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback